AZD0780

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

1

Byetta

AstraZeneca

Phase 3

—2

Zocor

OOrganon and Co

Phase 3

23

Zilebesiran

Alnylam Pharmaceuticals

Phase 3

—4

Repatha

Amgen

Preclinical

55

AZD0780

AstraZeneca

Phase 3

16

Praluent

Regeneron

Preclinical

17

Calciferol

Alnylam Pharmaceuticals

Preclinical

18

Benicar

Novartis

Preclinical

19

Farxiga

AstraZeneca

Preclinical

110

Mounjaro

Eli Lilly

Preclinical

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Phase II2 trials

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

Active, not recruiting·AstraZeneca·Phase 3·NCT07000136·455 enrolled

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

Active, not recruiting·AstraZeneca·Phase 3·NCT07000123·3,046 enrolled

Dyslipidaemia2 trials

A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia

Recruiting·AstraZeneca·Phase 2·NCT07218900·76 enrolled

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

Recruiting·AstraZeneca·Phase 2/3·NCT06834932·360 enrolled

Metformin1 trial

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

Completed·AstraZeneca·Phase 1·NCT07216131·14 enrolled

Hepatic Impairment1 trial

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Completed·AstraZeneca·Phase 1·NCT06576765·16 enrolled

Blood Pressure1 trial

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Completed·AstraZeneca·Phase 2·NCT06692764·202 enrolled

9 more indications

DME1 trial

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Completed·AstraZeneca·Phase 1·NCT05817461·8 enrolled

Statin1 trial

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Completed·AstraZeneca·Phase 1·NCT05787002·16 enrolled

Tics1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

Completed·AstraZeneca·Phase 1·NCT05384262·183 enrolled

Efficacy1 trial

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Completed·AstraZeneca·Phase 1·NCT06742853·81 enrolled

Drug Interactions1 trial

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

Completed·AstraZeneca·Phase 1·NCT06671405·59 enrolled

Renal Impairment1 trial

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Completed·AstraZeneca·Phase 1·NCT06592482·30 enrolled

Dyslipidemia1 trial

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

Completed·AstraZeneca·Phase 2·NCT06173570·428 enrolled

Cardiovascular Disease1 trial

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Recruiting·AstraZeneca·Phase 3·NCT07000357·15,100 enrolled

Unspecified1 trial

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Repeated Dose Administration to Healthy Adults With Elevated LDL-C Levels

Completed·AstraZeneca·Phase 1·NCT07423598·40 enrolled

Details

Drug Info

Related News